CMND

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. The company's lead candidate, CMND-100, is a proprietary MEAI-based oral drug in a Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD), being conducted at reputable clinical sites including Yale School of Medicine and Johns Hopkins University. MEAI (5-methoxy-2-aminoindane) is a next-generation, non-hallucinogenic neuroplastogen designed for the treatment of addiction-related disorders, weight loss, and other central nervous system (CNS) conditions. Clearmind's shares are listed on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under "CWY0," with a patent portfolio consisting of nineteen patent families including 31 granted patents.